Baird lowered the firm’s price target on Tandem Diabetes to $20 from $32 and keeps a Neutral rating on the shares. The firm said 3Q revenue was above the Street and likely a bit above buy-side expectations. But contraction in new U.S. pump shipments worsened and management again cut international revenue expectations for the year.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on TNDM: